These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32026322)

  • 1. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.
    Kashani B; Zandi Z; Karimzadeh MR; Bashash D; Nasrollahzadeh A; Ghaffari SH
    Immunol Res; 2019 Dec; 67(6):505-516. PubMed ID: 32026322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid).
    Kashani B; Zandi Z; Bashash D; Zaghal A; Momeny M; Poursani EM; Pourbagheri-Sigaroodi A; Mousavi SA; Ghaffari SH
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):47-59. PubMed ID: 31786654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anticancer effect of the TLR4 inhibition using TAK-242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer.
    Zandi Z; Kashani B; Bashash D; Poursani EM; Mousavi SA; Chahardoli B; Ghaffari SH
    J Cell Biochem; 2020 Feb; 121(2):1623-1634. PubMed ID: 31535397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.
    Zandi Z; Kashani B; Poursani EM; Bashash D; Kabuli M; Momeny M; Mousavi-Pak SH; Sheikhsaran F; Alimoghaddam K; Mousavi SA; Ghaffari SH
    Eur J Pharmacol; 2019 Jun; 853():256-263. PubMed ID: 30930249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
    Sun NK; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling.
    Sun T; Liu Y; Li M; Yu H; Piao H
    Mol Cell Probes; 2020 Oct; 53():101602. PubMed ID: 32447047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation.
    Baakhlagh S; Kashani B; Zandi Z; Bashash D; Moradkhani M; Nasrollahzadeh A; Yaghmaei M; Mousavi SA; Ghaffari SH
    Int Immunopharmacol; 2021 Jan; 90():107202. PubMed ID: 33278749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    Sootichote R; Thuwajit P; Singsuksawat E; Warnnissorn M; Yenchitsomanus PT; Ithimakin S; Chantharasamee J; Thuwajit C
    BMC Cancer; 2018 Feb; 18(1):231. PubMed ID: 29486738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
    Byun JM; Lee DS; Landen CN; Kim DH; Kim YN; Lee KB; Sung MS; Park SG; Jeong DH
    Acta Oncol; 2019 Nov; 58(11):1594-1602. PubMed ID: 31257975
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
    Chiba Y; Sato S; Itamochi H; Yoshino N; Fukagawa D; Kawamura H; Suga Y; Kojima-Chiba A; Muraki Y; Sugai T; Sugiyama T
    Int J Gynecol Cancer; 2017 Oct; 27(8):1666-1674. PubMed ID: 28786875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules.
    Matsunaga N; Tsuchimori N; Matsumoto T; Ii M
    Mol Pharmacol; 2011 Jan; 79(1):34-41. PubMed ID: 20881006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
    Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
    Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR4 is a novel determinant of the response to paclitaxel in breast cancer.
    Rajput S; Volk-Draper LD; Ran S
    Mol Cancer Ther; 2013 Aug; 12(8):1676-87. PubMed ID: 23720768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
    Zhang R; Yang X; Roque DM; Li C; Lin J
    PLoS One; 2021; 16(4):e0240145. PubMed ID: 33909625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
    Huang SL; Chang TC; Chao CCK; Sun NK
    Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
    Zhang R; Chen X; Fu S; Xu L; Lin J
    Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
    Seino M; Okada M; Sakaki H; Takeda H; Watarai H; Suzuki S; Seino S; Kuramoto K; Ohta T; Nagase S; Kurachi H; Kitanaka C
    Oncol Rep; 2016 Jan; 35(1):593-601. PubMed ID: 26534836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
    Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
    Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
    Chang YW; Singh KP
    PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.